Take a look at the Recent articles

Comorbidity of epilepsy and depression in adolescents

Sona E Aliyeva

Azerbaijan Medical State University, Department of Neurology Senior Assistant Baku City, Azerbaijan Republic

E-mail : bhuvaneswari.bibleraaj@uhsm.nhs.uk

Nadir A Aliyev

Azerbaijan State Advanced Training Institute for Doctors named by A. Aliyev department of psychiatry and drug addiction, PHD, MD, Baku, Azerbaijan Republic

Ayten K Mammadbayli

Azerbaijan Medical State University, Department of Neurology Senior Assistant Baku City, Azerbaijan Republic

Zafar N Aliyev

Azerbaijan Medical State University, Department of Psychiatry, Baku City, Azerbaijan Republic Azerbaijan Medical University

DOI: 10.15761/MHAR.1000185

Article
Article Info
Author Info
Figures & Data

Abstract

Objective: Despite the availability of literary data on the comorbidity of epilepsy and depression, in adolescents this problem is almost not developed.

Materials and Methods: The aim: to study the comorbidity of epilepsy and depression in children. The study included 31 patients with epilepsy. The severity of depression was studied by using the Hamilton scale and ICD-10.

Results: Depression of varying severity was detected in 51,62 % of the examined patients 13 cases of mild, 2 moderate and 1 case of severe depression without psychotic symptoms.

Conclusion: In children with epilepsy, there is a high incidence of comorbidity of epilepsy and depression.

Keywords

epilepsy, depression, comorbidity, adolescents

Introduction

Epidemiological studies show that epilepsy is one of the most common neurological diseases with certain mental disorders. Around 50 million people worldwide have epilepsy, making it one of the most common neurological diseases globally. Recurrent seizures are associated with a number of harmful effects. Seizure-related deaths can account for up to 40% of all deaths in patients with chronic epilepsy. The rate of sudden death, which accounts for 7-17% of deaths among patients with epilepsy, is estimated to be 27 times higher in patients with seizures than those who do not have seizures [1]. The incidence of epilepsy in the European countries and the United States is about 40-70 cases per 100,000 population, while in developing countries the incidence is much higher. It is interesting that the incidence of epilepsy in men, especially in old and senile age, is higher than that of women [2].

In medicine, it has long been known that people suffering from epilepsy, in addition to having seizures, also find other symptoms. Around 400 BC, Hippocrates observed that “melancholy usually becomes epileptics and epileptics become melancholic” [3,4].

Some authors indicates that depression deserves special attention due to its high frequency (10-30% of patients) and the risk of suicide occurring among epileptic patients is much more frequent than the average among population [5,6]. Further, the author believes that in addition to changes in the mood as a result of primary epileptic brain dysfunction, negative social stigmatization plays an important role in the development of depression, which leads to restrictions on education, occupation, social contacts, spending of free time.

According to various authors, depressive disorder in epilepsy occurs from 22% to 58% of patients [7]. In addition, the relationship between epilepsy and depression in the literature, the treatment of combined pathology, molecular basis etc. [8-10].

Materials and methods

Epilepsy is one of the most common neuropsychiatric diseases. In the adapted version of the ICD-10 revision (put in place by order No. 170 of the Ministry of Health of the Russian Federation of May 27, 1997) in class VI, diseases of the nervous system-disorders related to epilepsy are provided for only 15 headings (G40 Epilepsy-G40.0- G40.9; G41 Epileptic status - G41.0- G41.9). In class V, mental and behavioral disorders associated with epilepsy are treated in a 17 rubric. In other words, the number of mental and behavioral disorders associated with epilepsy is greater than that of neurological. Therefore, we consider it expedient to consider epilepsy as a neuropsychic disorder.

We examined 31 patients with G40.3 Generalized idiopathic epilepsy G 40.0 Focal epilepsy. Patients were examined in the interictal period

Patients were observed at the Children's neurological hospital of the Main Health Department of the city of Baku, Azerbaijan from January 2018 to February2019. Patients are randomized as they go to the children's neurological hospital. Clinical characteristics of enrolled children was shown in the Table 1.

Table 1. Clinical characteristics of enrolled children

Clinical characteristics

Total n = 31

Age at test (years) mean±m

14,0 ± 0,28

Gender n (%)

 

male

25 (81 %)

female

6 (19 %)

Epilepsy type

 

G40.3 Generalized idiopathic epilepsy

19 (62 %)

G 40.0 Focal epilepsy

12 (38 %)

Results

Results of this study were presented in the Table 2.

Table 2. Results of this study

Indicators

Total n = 31

The Hamilton scale in points

 

 

 

Norm 0-7  

Depression of varying severity:

Mild
moderate

severe depression without psychotic symptoms  

 

15(49%)

 

16(51%)

13(42%)

2(7%)

 

1(4%)

 Diagnosis of depression in

ICD-10

Depressive episodes (F32.0-32.2)

Epilepsy type and Depression

Depression in Generalized idiopathic epilepsy G40.

10 (62%)

Depression in Focal epilepsy G 40.0

6 (38%)

As can be seen from Table 2, Depression of varying severity was detected in 51,62 % of the examined patients 13 cases of mild, 2 moderate and 1 case of severe depression without psychotic symptoms. Depression in Generalized idiopathic epilepsy about two times more common than in Focal epilepsy.

The data obtained by us in connection with a small number of patients and a short period of observation should be considered preliminary. The next stage of the work will be carried out on a large number of patients and longer duration of observation. Contrary to generally accepted norms, in boys with epilepsy, depression is more common than for girls.

Discussion

From literature it is known that among people with epilepsy, depression is extremely common and is associated with intense personal suffering and a sharp decline in the quality of life [11]. According to other systematic review, 23.1% of people with epilepsy suffer from depression during the past year, compared with 6.6% in the general population [12,13]. The lifetime prevalence of depression is estimated to be 30–35% among people with epilepsy, compared with 16.2% in the general population [3,14].

The results study of Swinkels, et al. [15] show a higher prevalence of mood and anxiety disorders in patients with epilepsy, compared with the general population. They found that the subgroup of temporal lobe epilepsy patients, in particular, suffer from these disorders. But they cannot exclude that some methodological short- comings in their design may have obscured more pronounced differences between the TLE and extra-TLE subgroups [15].

In TLE affective disorders are important comorbidities, primarily due to suicidal potential in all its forms, including gestures, thoughts, or successful attempts, which range from 10% to 15% in patients versus 1–1.5% in the general population [16].

According some literature data the prevalence of depression occurs 5 times more often in patients with controlled seizures and 10 times in patients with uncontrolled. It is not known whether depression in these patients can be considered primarily as part of the primary pathology of the central nervous system or as a clear response to an epileptic disorder with all the difficulties of daily coping [17].

It is believed that the biological factors is include hypometabolism in extratemporal regions, hippocampal dysfunction or atrophy, and 5-HT1A-receptor-binding abnormality among other factors [18]. As Canner noted, the presence of a psychiatric disease, in particular depression can be associated with additional difficulties in controlling seizures, which makes this form of TLE more resistant to treatment [19].

In his review article, Kanner lists the following general pathogenetic mechanisms of depression and epilepsy listed the following pathogenic mechanisms shared by depression and epilepsy [20]:

• Abnormal CNS activity of several neurotransmitters, particularly serotonin (5-hydroxytryptamine, 5-HT), norepinephrine, dopamine, GABA, and glutamate.

• Structural changes, presenting as atrophy of temporal- and frontal-lobe structures (identified by high-resolution MRI and volumetric measurements), in the amygdala, hippocampus, entorhinal cortex, temporal lateral neocortex, as well as in the prefrontal, orbito-frontal, and mesial-frontal cortex, and to a lesser degree, of the thalamic nuclei and basal ganglia.

• Functional abnormalities (identified by positron emission tomography [PET] and single-photon emission computed tomography [SPECT]) in temporal and frontal lobes, consisting of decreased 5-HT1A binding in the mesial structures, raphe nuclei, thalamus, and cingulate gyrus.

• Abnormal function of the hypothalamic–pituitary–adrenal axis

Kanner and co-authors [21] write: “In summary, the data presented here suggest the negative impact of depressive disorders on the course and response to treatment of seizure disorders. We propose several hypotheses to explain this phenomenon. Contrary to old beliefs, the relatively high comorbidity between de- pression and epilepsy is not only the expression of a reactive process whereby patients face multiple obstacles associated with a life with seizures. The data presented in this review strongly suggest the existence of common neurobiologic pathogenic mechanisms that may play a pivotal role in the high comorbidity of these two conditions. The impact of these pathogenic mechanisms is not limited to high comorbidities but can play a major role in the worst case scenario and can respond to the pharmacological and surgical treatment of convulsive disorders in patients with seizure to lifelong depression. Whether early recognition and treatment of depressive disorders would change the impact on the higher risks that patients with depression have of developing epilepsy and on their response to therapy remains to be established”.

The lack of treatment and detection of depressive disorders in people with epilepsy has serious consequences at several levels:

1. Increased suicide risk. Depression in patients with epilepsy is associated with a significantly higher suicide rate than in the general population.

2. Negative impact on quality of life. Pharmacoresistant epilepsy showed that depression is the most powerful predictor of a decrease in the quality of life associated with health.

3. The impact on the cost and use of medical services. Depression in people with epilepsy significantly increases the health costs associated with treating convulsive disorders. The presence and severity of depression were predictors of lower rates of disability, regardless of the duration of the convulsive disorder.

The limitation of our work: 1) a small number of patients; 2) a short time observation.

Thus, for a group of examined patients with epilepsy in more than half of cases, depression is characterized to a certain degree of severity. The study of comorbidity of epilepsy and depression is of great theoretical and practical importance. First, it will contribute to the early detection of depression. Second, prevent suicides. Third, it will help reduce refractory epilepsy. Finally, improve their quality of life for patients with epilepsy.

Funding

The article carried out by own financial resource.

Author disclosure

Authors declare that the manuscript is submitted on behalf of all authors. None of the material in this manuscript have been published previously in any form and none of the material is currently under consideration for publication elsewhere other than noted in the cover letter to the editor. Authors declare to have any financial and personal relationship with other people or organizations that could inappropriately influence this work. All authors contributed to and have approved the final manuscript.

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

  1. Neurological Disorders: Public Health Challenge (2010) Global Burden of Neurological Disorders, World Health Organization.
  2. Wolf P (2003) Praxisbuch Epilepsien. Diagnostik, Behandlung, Rehabilitation – Kohlhammer, Stuttgart 394.
  3. Victoroff JI, Benson F, Grafton ST, Engel J Jr, Mazziotta JC (1994) Depression in complex partial seizures. Electroencephalography and cerebral metabolic correlates. Arch Neurol 51: 155-163. [Crossref]
  4. Cardamone L, Salzberg MR, O'Brien TJ, Jones NC (2013) Antidepressant therapy in epilepsy: can treating the comorbidities affect the underlying disorder? Br J Pharmacol 168: 1531-1554. [Crossref]
  5. Kanner AM (2006) Depression and epilepsy: a new perspective on two closely related disorders. Epilepsy Curr 6: 141-146. [Crossref]
  6. Kanner AM (2007) Epilepsy and mood disorders. Epilepsia 48 Suppl 9: 20-22.
  7. Kanner AM (2008) Depression in epilepsy: a complex relation with unexpected consequences. Curr Opin Neurol 21: 190-194. [Crossref]
  8. Mula M, Schmitz B, Sander JW (2008) The pharmacological treatment of depression in adults with epilepsy. Expert Opin Pharmacother 9: 3159-3168. [Crossref]
  9. Mula M1, Hesdorffer DC (2011) Suicidal behavior and antiepileptic drugs in epilepsy: analysis of the emerging evidence. Drug Healthc Patient Saf 3: 15-20. [Crossref]
  10. Aliyev NA, Aliyev ZN, Aliyeva SE (2018) Selective neuronal potassium channel opener (SNEPCO) flupirtine in treatment-resistant epilepsy comorbid depression in adults. Ment Health Addict Res 3: 4-5.
  11. Gilliam F, Hecimovic H, Sheline Y (2003) Psychiatric comorbidity, health, and function in epilepsy. Epilepsy Behav 4: 26-30. [Crossref]
  12. Fiest KM, Dykeman J, Patten SB, Wiebe S, Kaplan GG, et al. (2013) Depression in epilepsy a systematic review and meta-analysis. Neurology 80: 590-599. [Crossref]
  13. Kupfer DJ, Frank E, Phillips ML (2012) Major depressive disorder: new clinical, neurobiological, and treatment perspectives. The Lancet 379: 1045-1055. [Crossref]
  14. Kanner AM, Schachter SC, Barry JJ, Hersdorffer DC, Mula M, et al. (2012) Depression and epilepsy: epidemiologic and neurobiologic perspectives that may explain their high comorbid occurrence. Epilepsy Behav 24:156-168. [Crossref]
  15. Swinkels J WAM, Kuyk EH de Graaf, van Dyck R, Ph Spinhoven (2001) Prevalence of Psychopathology in Dutch Epilepsy Inpatients: A Comparative Study. Epilepsy Behav 2: 441-447. [Crossref]
  16. Jones JE, Hermann BP, Woodard JL, Barry JJ, Gilliam F, et al. (2005) Screening for major depression in epilepsy with common self-report depression inventories. Epilepsia 46: 731-735. [Crossref]
  17. Harden CL1, Goldstein MA (2002) Mood disorders in patients with epilepsy: epidemiology and management. CNS Drugs 16: 291-302. [Crossref]
  18. Hasler G, Bonwetsch R, Giovacchini G, Toczek MT, Bagic A, et al. (2007) 5-HT1A receptor binding in temporal lobe epilepsy patients with and without major depression. Biol Psychiatry 62: 1258-1264. [Crossref]
  19. Kanner AM (2004) Do epilepsy and psychiatric disorders share common pathogenic mechanisms? A look at depression and epilepsy. Clinical Neuroscience Research 4: 31-37.
  20. Kanner AM (2005) Current review in clinical science: depression in epilepsy: a neurobiologic perspective. Epilepsy Curr 5: 21-27. [Crossref]
  21. Kanner AM, Schachter SC, Barry JJ, Hersdorffer DC, Mula M, et al. (2012) Depression and epilepsy: Epidemiologic and neurobiologic perspectives that may explain their high comorbid occurrence. Epilepsy Behav 24: 156-168. [Crossref]

Editorial Information

Editor-in-Chief

Jeffrey L. Derevensky
McGill University

Article Type

Research Article

Publication history

Received: July 01, 2019
Accepted: July 22, 2019
Published: July 25, 2019

Copyright

©2019 Aliyev SE, Aliyev NA, Mammadbayli AK, Aliyev ZN. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Citation

Aliyeva SE (2019) Comorbidity of epilepsy and depression in adolescents. Ment Health Addict Res 5: DOI: 10.15761/MHAR.1000185

Corresponding author

Nadir A. Aliyev PH.D., MD

Department of Psychiatry and Addiction Azerbaijan State Advanced Training Institute for Doctors named by A. Aliyev, department of psychiatry and addiction, Baku, Azerbaijan; Baku City, U. Chagibekov Street, 46/50, F. 1. Baku P.O. AZ0010, Azerbaijan Republic.

E-mail : bhuvaneswari.bibleraaj@uhsm.nhs.uk

Table 1. Clinical characteristics of enrolled children

Clinical characteristics

Total n = 31

Age at test (years) mean±m

14,0 ± 0,28

Gender n (%)

 

male

25 (81 %)

female

6 (19 %)

Epilepsy type

 

G40.3 Generalized idiopathic epilepsy

19 (62 %)

G 40.0 Focal epilepsy

12 (38 %)

Table 2. Results of this study

Indicators

Total n = 31

The Hamilton scale in points

 

 

 

Norm 0-7  

Depression of varying severity:

Mild
moderate

severe depression without psychotic symptoms  

 

15(49%)

 

16(51%)

13(42%)

2(7%)

 

1(4%)

 Diagnosis of depression in

ICD-10

Depressive episodes (F32.0-32.2)

Epilepsy type and Depression

Depression in Generalized idiopathic epilepsy G40.

10 (62%)

Depression in Focal epilepsy G 40.0

6 (38%)